Compare HTFL & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HTFL | TRVI |
|---|---|---|
| Founded | 2007 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 1.8B |
| IPO Year | 2025 | 2019 |
| Metric | HTFL | TRVI |
|---|---|---|
| Price | $57.56 | $13.41 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 11 |
| Target Price | ★ $50.50 | $28.18 |
| AVG Volume (30 Days) | 1.3M | ★ 2.5M |
| Earning Date | 11-12-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 82.37 | 31.91 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $176,034,000.00 | N/A |
| Revenue This Year | $41.24 | N/A |
| Revenue Next Year | $24.11 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 39.92 | N/A |
| 52 Week Low | $20.13 | $9.82 |
| 52 Week High | $57.74 | $20.22 |
| Indicator | HTFL | TRVI |
|---|---|---|
| Relative Strength Index (RSI) | 69.75 | 47.88 |
| Support Level | $46.46 | $13.08 |
| Resistance Level | N/A | $13.55 |
| Average True Range (ATR) | 2.89 | 0.67 |
| MACD | 0.64 | 0.18 |
| Stochastic Oscillator | 90.75 | 92.05 |
HeartFlow Inc is a commercial-stage medical technology company that provides software and artificial intelligence (AI) designed to deliver a non-invasive solution for diagnosing and managing coronary artery disease. The company operates and manages its business as a single reportable operating segment: non-invasive coronary artery disease detection solutions. Geographically, it operates in the United States and the rest of Europe, deriving the majority of its revenue from the United States. The company has developed three software products: Heartflow Roadmap Analysis, Heartflow FFRCT Analysis, and Heartflow Plaque Analysis.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.